Does Rallies show 13F holders for TNDM?

Yes. Rallies tracks hedge fund and 13F ownership data for TNDM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TNDM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TNDM. It does not provide personalized investment advice.

TNDM (Tandem Diabetes Care, Inc.) Stock Analysis - Hedge Fund Holdings

Tandem Diabetes Care, Inc. (TNDM) is a publicly traded Healthcare sector company. As of May 21, 2026, TNDM trades at $14.89 with a market cap of $927.20M and a P/E ratio of -10.46. TNDM moved +8.51% today. Year to date, TNDM is -35.03%; over the trailing twelve months it is -36.05%. Its 52-week range spans $9.98 to $45.28. Analyst consensus is buy with an average price target of $30.76. Rallies surfaces TNDM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TNDM stock?

Hedge funds tracked by Rallies that own TNDM include Panagora Asset, Mangrove Partners, Bridgewater Associates, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Tandem Diabetes Care, Inc..

TNDM Key Metrics

Key financial metrics for TNDM
Metric	Value
Price	$14.89
Market Cap	$927.20M
P/E Ratio	-10.46
EPS	$-1.40
Dividend Yield	0.00%
52-Week High	$45.28
52-Week Low	$9.98
Volume	2.81K
Avg Volume	0
Revenue (TTM)	$1.03B
Net Income	$-94.55M
Gross Margin	54.93%

Top Hedge Funds Holding TNDM

Panagora Asset holds 163.69K shares of TNDM, changed +11.94% as of Mar 31, 2026.
Mangrove Partners holds 82.43K shares of TNDM, changed +69.11% as of Mar 31, 2025.
Bridgewater Associates holds 7.38K shares of TNDM, changed -71.22% as of Dec 31, 2024.
Centerbook Partners holds 6.93K shares of TNDM, changed +0.00% as of Dec 31, 2023.

Latest TNDM News

Tandem Diabetes Care Exceeds $1B Sales, Prepares Three New Pump Launches — Mar 3, 2026
Tandem Posts 58% Q4 Margin, Eyes Pharmacy Shift with $70–80M Headwind and “Toby” FDA Bid — Mar 2, 2026
Tandem Diabetes Upsizes $265M Convertible Notes at 37.5% Premium — Feb 25, 2026
Brown Capital Exits Tandem Diabetes Care Despite $290M Q4 Sales and 15% Growth — Feb 23, 2026
Tandem Diabetes Q4 Sales Rise 15% to $290.4M Drives 30% Stock Rally — Feb 20, 2026

Recent TNDM Insider Trades

Novara Mark David sold 187 (~$4.31K) on Mar 17, 2026.
Novara Mark David sold 2 (~$45.62) on Mar 5, 2026.
Sheridan John F bought 10.00K (~$102.32K) on Aug 11, 2025.

TNDM Analyst Consensus

18 analysts cover TNDM: 0 strong buy, 9 buy, 9 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.76.

Common questions about TNDM

Who owns TNDM stock?: Hedge funds tracked by Rallies that own TNDM include Panagora Asset, Mangrove Partners, Bridgewater Associates, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Tandem Diabetes Care, Inc..
Does Rallies show 13F holders for TNDM?: Yes. Rallies tracks hedge fund and 13F ownership data for TNDM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TNDM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TNDM. It does not provide personalized investment advice.